<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03761017</url>
  </required_header>
  <id_info>
    <org_study_id>CP-MGD019-01</org_study_id>
    <nct_id>NCT03761017</nct_id>
  </id_info>
  <brief_title>MGD019 DART® Protein in Unresectable/Metastatic Cancer</brief_title>
  <official_title>A Phase 1, First-in-Human, Open-Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD-1 and CTLA-4 in Patients With Unresectable or Metastatic Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MacroGenics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MacroGenics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK)&#xD;
      pharmacodynamics and preliminary antitumor activity of MGD019.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 1, open-label study will characterize safety, dose-limiting toxicities (DLTs), and&#xD;
      maximum tolerated/administered dose (MTD/MAD) of MGD019. Dose escalation will occur in a&#xD;
      3+3+3 design in patients with advanced solid tumors of any histology. Once the MTD/MAD is&#xD;
      determined, a Cohort Expansion Phase will be enrolled to further characterize safety and&#xD;
      initial anti-tumor activity in patients with specific tumor types anticipated to be sensitive&#xD;
      to dual checkpoint blockade.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>3+3+3 dose escalation design followed by cohort expansion at the recommended Phase 2 dose.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>30 days after last dose</time_frame>
    <description>Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of study drug administration through the End of Study visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 108 weeks</time_frame>
    <description>Maximum Plasma Concentration of MGD019</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>up to 108 weeks</time_frame>
    <description>Time to reach maximum (peak) plasma concentration of MGD019</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>up to 108 weeks</time_frame>
    <description>Area Under the Plasma Concentration versus Time Curve of MGD019</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough</measure>
    <time_frame>up to 108 weeks</time_frame>
    <description>Trough plasma concentration of MGD019</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>up to 108 weeks</time_frame>
    <description>Total body clearance of the drug from plasma of MGD019</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vss</measure>
    <time_frame>up to 108 weeks</time_frame>
    <description>Apparent volume of distribution at steady state of MGD019</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>up to 108 weeks</time_frame>
    <description>Terminal half life of MGD019</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients with anti-drug antibodies against MGD019</measure>
    <time_frame>up to 108 weeks</time_frame>
    <description>Immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary anti-tumor activity of MGD019</measure>
    <time_frame>Every 12 - 24 weeks while patient is on treatment</time_frame>
    <description>Efficacy assessed using conventional Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic progression-free survival (PFS) in metastatic castration-resistant prostate cancer (mCRPC)</measure>
    <time_frame>up to 2 years post last treatment</time_frame>
    <description>Time from first dose to first occurrence of radiographic progression, or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate specific antigen (PSA) response rate in mCRPC</measure>
    <time_frame>up to 2 years post last treatment</time_frame>
    <description>Percent of patients with 50% or more decline in PSA and confirmed 3 weeks later</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best PSA percent change in mCRPC</measure>
    <time_frame>up to 2 years post last treatment</time_frame>
    <description>Best percent change in PSA from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of PSA response</measure>
    <time_frame>up to 2 years post last treatment</time_frame>
    <description>Time from PSA response to time of PSA progression</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">287</enrollment>
  <condition>Squamous Cell Non Small Cell Lung Cancer</condition>
  <condition>Prostate Cancer Metastatic</condition>
  <condition>Cutaneous Melanoma</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Advanced Cancer</condition>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>MGD019</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bispecific DART protein binding PD-1 and CTLA-4</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MGD019</intervention_name>
    <description>Bispecific DART protein binding PD-1 and CTLA-4</description>
    <arm_group_label>MGD019</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Dose escalation: Patients with histologically proven, unresectable, locally advanced&#xD;
             or metastatic solid tumors for whom no approved therapy with demonstrated clinical&#xD;
             benefit is available or patients who are intolerant to standard therapy.&#xD;
&#xD;
          -  Cohort Expansion Phase:&#xD;
&#xD;
          -  Checkpoint inhibitor-naïve squamous cell NSCLC, including:&#xD;
&#xD;
               1. Patients that have progressed during or following treatment with platinum-based&#xD;
                  chemotherapy for advanced disease. Patients harboring an activating epidermal&#xD;
                  growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK)&#xD;
                  rearrangement must have progressed following at least one available EGFR or ALK&#xD;
                  targeted therapy. ROS1 rearrangement or BRAF mutation must have progressed&#xD;
                  following at least 1 available EGFR (including osimertinib for EGFR T790M-mutated&#xD;
                  NSCLC), ALK, ROS1 or BRAF targeted therapy, respectively&#xD;
&#xD;
               2. Patients that have progressed during or following treatment with platinum-based&#xD;
                  chemotherapy for advanced disease and patients with previously untreated squamous&#xD;
                  cell NSCLC without activating mutations for whom checkpoint inhibitor therapy is&#xD;
                  not approved or available.&#xD;
&#xD;
          -  Advanced non-microsatellite instability-high colorectal cancer (CRC) with recurrence,&#xD;
             progression, or intolerance to standard therapy consisting of at least 2 prior&#xD;
             standard regimens. CRC harboring an activating EGFR mutation must have progressed&#xD;
             during or following at least one available EGFR targeted therapy. Patients who are&#xD;
             inappropriate candidates for or have refused treatment with these regimens are also&#xD;
             eligible. Patients should have received no more than 4 prior lines of systemic&#xD;
             therapy.&#xD;
&#xD;
          -  Checkpoint inhibitor-naïve mCRPC that has progressed during or following no more than&#xD;
             2 prior lines of an androgen receptor antagonist or androgen synthesis inhibitor&#xD;
             (e.g., enzalutamide or abiraterone, respectively), if approved and available, with a&#xD;
             PSA value of at least 2 ng/mL and meeting at least one of the following:&#xD;
&#xD;
          -  Progression in measurable disease (RECIST v1.1).&#xD;
&#xD;
          -  Appearance of 2 or more new bone lesions according to Prostate Cancer Working Group 2&#xD;
             (PCWG-2).&#xD;
&#xD;
          -  Rising PSA defined as at least two sequential rises in PSA.&#xD;
&#xD;
          -  Eligible patients may have received prior chemotherapy (i.e. docetaxel), and patients&#xD;
             with known homologous recombination (HRR) pathway gene alterations must have received&#xD;
             the applicable approved therapy (e.g. olaparib).&#xD;
&#xD;
          -  Cutaneous melanoma that has progressed during or following systemic treatment for&#xD;
             unresectable, locally advanced, or metastatic disease. Patients will have received&#xD;
             PD-(L)1 and/or CTLA-4 pathway inhibitors where available and indicated.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks.&#xD;
&#xD;
          -  Measurable disease as per RECIST 1.1 for the purpose of response assessment must&#xD;
             either (a) not reside in a field that has been subjected to prior radiotherapy or (b)&#xD;
             have demonstrated clear evidence of radiographic progression since the completion of&#xD;
             prior radiotherapy and prior to study enrollment.&#xD;
&#xD;
          -  All patients must have an identified formalin-fixed, paraffin embedded (FFPE) tumor&#xD;
             specimen (up to 20 slides or a block) for immunohistochemical evaluation of&#xD;
             pharmacodynamic markers of interest. Patients may undergo a fresh tumor biopsy during&#xD;
             the screening period if a tumor sample is not available. Patients in the mCRPC&#xD;
             expansion cohort with bone only disease not amenable to fresh biopsy may be eligible&#xD;
             in consultation with the Sponsor.&#xD;
&#xD;
          -  Acceptable laboratory parameters and adequate organ reserve.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  In patients who have previously received an immune checkpoint inhibitor (e.g.,&#xD;
             anti-PD-L1, anti-PD-1, anti-CTLA-4), toxicities related to the checkpoint inhibitor&#xD;
             must have resolved to ≤ Grade 1 or baseline. Patients with well controlled immune&#xD;
             endocrinopathies secondary to prior checkpoint therapy are eligible.&#xD;
&#xD;
          -  Patients with symptomatic CNS metastases. Patients with history of prior CNS&#xD;
             metastasis must have been treated, must be asymptomatic, and must not have concurrent&#xD;
             treatment for the CNS disease, progression of CNS metastases on magnetic resonance&#xD;
             imaging (MRI) or computed tomography (CT) for at least 14 days after last day of prior&#xD;
             therapy for the CNS metastases, or concurrent leptomeningeal disease or cord&#xD;
             compression.&#xD;
&#xD;
          -  Patients who sustained the following Grade 3 immune checkpoint inhibitor related AEs&#xD;
             are ineligible: Ocular AE, changes in liver function tests that met the criteria for&#xD;
             Hy's law (&gt; 3 × ULN of either ALT or AST with concurrent &gt; 2 × ULN of total bilirubin&#xD;
             and without alternate etiology), neurologic toxicity, colitis, renal toxicity,&#xD;
             pneumonitis.&#xD;
&#xD;
          -  Patients who have received prior therapy with a combination of monoclonal antibodies&#xD;
             against PD-1/PD-L1 and CTLA-4 will be excluded in the Cohort Expansion (this does not&#xD;
             apply to the melanoma expansion cohort).&#xD;
&#xD;
          -  Patients with any history of known or suspected autoimmune disease with certain&#xD;
             exceptions&#xD;
&#xD;
          -  History of prior allogeneic bone marrow, stem-cell, or solid organ transplantation.&#xD;
&#xD;
          -  History of trauma or major surgical procedure within 4 weeks prior to initiation of&#xD;
             study drug administration.&#xD;
&#xD;
          -  Systemic antineoplastic therapy, or investigational therapy (for all tumor types) or&#xD;
             androgen receptor antagonist/androgen synthesis inhibitor for mCRPC (e.g.,&#xD;
             enzalutamide or abiraterone, respectively) within the 4 weeks prior to initiation of&#xD;
             study drug administration.&#xD;
&#xD;
          -  Treatment with radiation therapy within 2 weeks prior to initiation of study drug&#xD;
             administration.&#xD;
&#xD;
          -  Radioligand (e.g., radium-223) within 6 months prior to initiation of study drug&#xD;
             administration for mCRPC in the Cohort Expansion Phase.&#xD;
&#xD;
          -  Serum testosterone &gt; 50 ng/dl or &gt; 1.7 nmol/L for mCRPC in the Cohort Expansion Phase.&#xD;
&#xD;
          -  Confirmed or presumed COVID-19/SARS-CoV-2 infection. While SARS-CoV-2 testing is not&#xD;
             mandatory for study entry, testing should follow local clinical practice&#xD;
             guidelines/standards. Patients with a positive test result for SARS-CoV-2 infection,&#xD;
             known asymptomatic infection, or presumed infection are excluded. Patients may be&#xD;
             considered eligible after a resolved SARS-CoV-2 infection once he or she remains&#xD;
             afebrile for at least 72 hours and after other SARS-CoV-2-related symptoms have fully&#xD;
             recovered to baseline for a minimum of 72 hours&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bradley Sumrow, MD</last_name>
    <role>Study Director</role>
    <affiliation>MacroGenics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rosetta Cavallo</last_name>
    <phone>240.552.8104</phone>
    <email>cavallor@macrogenics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sejal Batra</last_name>
      <phone>617-726-2000</phone>
      <email>SBATRA4@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Cote, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>START Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie L. Robinson, BSN, RN</last_name>
      <phone>616-389-1739</phone>
      <email>Katie.Robinson@startmidwest.com</email>
    </contact>
    <investigator>
      <last_name>Manish Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Lopez</last_name>
      <phone>503-215-2614</phone>
      <email>CanRsrchStudies@providence.org</email>
    </contact>
    <investigator>
      <last_name>Rachel Sanborn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krystle Easton</last_name>
      <phone>412-623-7957</phone>
      <email>mientkiewiczk@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Luke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Sarah Cannon Research Institute / Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheetal Champaneria</last_name>
      <phone>615-329-6875</phone>
      <email>Sheetal.Champaneria@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Johanna Bendell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complex Oncology Center - Burgas&quot; EOOD, Department of Medical Oncology</name>
      <address>
        <city>Burgas</city>
        <zip>8000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complex Oncology Center - Ruse EOOD</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Mulitprofile Hospital for Active Treatment &quot;Sv. Ivan Rilski</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinical Centre, Early Clinical Trials Unit</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Europejskie Centrum Zdrowia Otwock</name>
      <address>
        <city>Otwock</city>
        <zip>05-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Med-Polonia Sp. z.o.o.</name>
      <address>
        <city>Poznań</city>
        <zip>60-693</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LUX MED Onkologia Sp. z.o.o.</name>
      <address>
        <city>Warszawa</city>
        <zip>01-748</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ICO Badalona / Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Ruber Internacional</name>
      <address>
        <city>Madrid</city>
        <zip>20834</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762776/</url>
    <description>Link to published 2020 manuscript</description>
  </link>
  <reference>
    <citation>Berezhnoy A, Sumrow BJ, Stahl K, Shah K, Liu D, Li J, Hao SS, De Costa A, Kaul S, Bendell J, Cote GM, Luke JJ, Sanborn RE, Sharma MR, Chen F, Li H, Diedrich G, Bonvini E, Moore PA. Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. Cell Rep Med. 2020 Dec 22;1(9):100163. doi: 10.1016/j.xcrm.2020.100163. eCollection 2020 Dec 22.</citation>
    <PMID>33377134</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 29, 2018</study_first_submitted>
  <study_first_submitted_qc>November 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2018</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Checkpoint blockade</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

